Busulfan Therapy in Myeloid Metaplasia

1. Seven patients with myeloid metaplasia, massive splenomegaly and hypermetabolism were treated with busulfan in eight courses of therapy. In each instance, reduction in spleen size and improvement of symptoms occurred.

2. The total dose of busulfan in five of the cases ranged between 212 and 290 mg. Three of the patients developed leukopenia of moderate degree necessitating discontinuance of drug therapy.

3. It would appear that initial and maintenance doses of busulfan should be lower in patients with myeloid metaplasia than the doses customarily used in the treatment of patients with chronic myclocytic leukemia.